Research
Hormonal
Genetic loss-of-function variants in the GIP receptor are associated with lower body mass index (BMI) and protection against obesity in humans.
Large-scale genetic studies show that people with naturally reduced GIP receptor function tend to have lower body weight. This suggests that therapies designed to block or antagonize the GIP receptor could be effective for treating obesity and type 2 diabetes.
StrongSupportsVERY_HIGH confidence
Here, phenotypic studies combined with genome-wide association studies (GWAS) in human carriers of LoF variants have supported protection against obesity [119]. Thus, a GWAS study combining data from 718,734 individuals identified variants of the GIPR gene among the few associated with a lower BMI [119].
Why this rating
Based on a massive GWAS study of 718,734 individuals, providing robust population-level evidence.
Source
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
Mette M. Rosenkilde et al. · Peptides · 2024
narrative_reviewCited 15×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →